Skip to main content

Checkmate Pharmaceuticals, Inc.

CMPIDelisted May 31, 2022
Industry
Biological Products, (No Diagnostic Substances)
SEC CIK
0001651431

Checkmate Pharmaceuticals, Inc. was delisted on May 31, 2022; its insiders filed their last Form 4 on May 31, 2022; 26 institutions reported holding it in 13F filings for Q1 2022, worth $54.8M in total; no superinvestor held it.

Q2 2022 vs. Q1 2022

How the institutions holding Checkmate Pharmaceuticals, Inc. changed between Q1 2022 and Q2 2022.

All holders in Q2 2022All holders in Q1 2022

13F holders of CMPI: Q1 2022 compared with Q2 2022
MeasureQ1 2022Q2 2022Change
Holders260−26
Shares17.2M0−17.2M (−100.0%)
Value$54.8M$0−$54.8M (−100.0%)

New holders (0)

Institutions that held Checkmate Pharmaceuticals, Inc. at the end of Q2 2022 but not at the end of Q1 2022.

None.

Sold out (26)

Institutions that held Checkmate Pharmaceuticals, Inc. at the end of Q1 2022 and filed for Q2 2022 without it.

Institutions that sold out of CMPI in Q2 2022
InstitutionShares, Q1 2022Value, Q1 2022
venBio Partners LLC3,673,374$11.7M
Sofinnova Investments, Inc.3,606,707$11.5M
Novo Holdings A/S2,161,990$6.90M
Medicxi Ventures Management (Jersey) Ltd1,501,716$4.79M
Omega Fund Management, LLC1,335,050$4.26M
Decheng Capital Management III (Cayman), LLC1,333,254$4.25M
Clough Capital Partners L P1,137,764$3.63M
FMR LLC966,226$3.08M
Vanguard Group Inc556,423$1.77M
Sectoral Asset Management Inc541,765$1.73M
Bridgeway Capital Management, LLC106,500$340.0K
RBF Capital, LLC68,034$219.0K
BlackRock Inc.51,334$164.0K
Geode Capital Management, LLC41,466$132.0K
Federated Hermes, Inc.30,636$98.0K
Cambridge Trust Co24,609$79.0K
Barclays PLC14,553$46.0K
State Street Corp11,424$36.0K
Morgan Stanley3,005$10.0K
US Bancorp2,000$6.00K
Tower Research Capital LLC (TRC)1,940$6.00K
UBS Group AG183$1.00K
Johnson Midwest Financial, LLC200$1.00K
JPMorgan Chase & Co49$0
Bank of America Corp1$0
Wells Fargo & Company33$0